Yesterday’s UN High Level Meeting on TB went well. Everyone was happy that TB finally came out of shadows and got the attention of the UN. The political declaration was approved. But few heads of states attended the HLM, and that was disappointing. Out of the 190+ member states, only about 30 leaders attended the HLM. This was a historic opportunities for high TB burden countries to step up and show leadership. But heads of India, China, Brazil and Russia were missing. President Ramaphosa from South Africa was there, along with Minister Motsoaledi. SA really showed leadership and we were hoping for more countries to do that.
Canada was represented by Min Philpott, ITK leaders, Theresa Tam, Howard Njoo, and others. No new commitments were made. The Canadian delegation was rather subdued.
Most statements were general and no hard funding or other commitments were made. Notable exceptions were commitments from the USAID and DFID. USAID launched Global Accelerator to End TBhttps://www.usaid.gov/news-information/press-releases/sep-26-2018-usaid-administrator-mark-green-announces-new-approach-end-tuberculosis. DFID is giving funds to TB Alliance and Oxford for sequencing research.https://reliefweb.int/report/world/uk-leads-fight-against-increasing-drug-resistant-tb
I had a couple of opportunities to speak and videos are here:
Director of the TB Centre
September 27, 2018
TB-oriented and other courses at the McGill Summer Institute in Infectious Diseases and Global Health
- Tuberculosis fight to get $13B USD a year
- Madhukar Pai at the UN General Assembly: High-level meeting on the fight against tuberculosis - Multi-stakeholder Panel 2
- Fight to End TB - SDG Media Zone at the 73rd session of United Nations General Assembly
- New study uncovers vast variation and significant deficits in tuberculosis care in urban India
- Backstory Podcast: Dr. Madhukar Pai discusses the UN High Level Meeting to End TB
- ‘Latent’ Tuberculosis? It’s Not That Common, Experts Find
- Complete make-over in the fight of multidrug-resistant tuberculosis
- August winner of the Relève étoile Jacques-Genest award
- Quatre mois pour soigner la tuberculose latente
- “Game changer” in TB treatment out of MUHC
- Have we misunderstood TB's timeline?
- WHO announces landmark changes in MDR-TB treatment regimens
- Click here for more
Congratulations to Dick Menzies:
THE NEW ENGLAND JOURNAL OF MEDICINE: Watch video of Dr. Menzies talking about his studies
- Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. Menzies D et al.N Engl J Med.August 2, 2018;379:440-453 Read article
- Safety and Side Effects of Rifampin versus Isoniazid in Children. Diallo T et al.N Engl J Med.August 2, 2018; 379:454-463 Read articleWatch video of Dr. Menzies talking about his study
- Treatment correlates of successful outcomes inpulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Ahmad N et al.The Lancet. September 8, 2018;392(10150):821-834 Read article
Beyond Killing Tuberculosis
Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease. However, this perspective has recently been challenged as scientists have taken a lesson from plant biologists about an ancient strategy involving the ability to “tolerate” rather than “resist” infection to maintain health. This concept, referred to as “disease tolerance”, provides an opportunity to develop new strategies that mitigate the consequences of infection. Read more
Eva Kaufman, August winner 2018 of the Relève étoile Jacques-Genest award
Eva Kaufmann, a postdoctoral fellow in Medicine at McGill University, is the award winner of the Relève étoile Jacques-Genest award of the Fonds de recherche du Québec – Santé (FRQS).Her Award-winning publication: BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosisis published in Cell. Congratulations Eva! More details
Great job at knowledge synthesis by TB Centre researchers:
Just got designated as a ‘Highly cited paper’ by the Web of Science, meaning it is among the top 1% of papers of similar age in the field of clinical medicine! Read it here: http://go.nature.com/2Da2w2q
McGill authors topped the rankings as first and corresponding authors in systematic reviews and meta-analyses in TB research.
According to a study, McGill researchers account for 6% of the world's best cited TB papers which is very high ranking! The 100 top-cited tuberculosis research https://www.atsjournals.org/doi/10.1164/rccm.201707-1489PPstudies (International Union Against Tuberculosis and Lung Disease) Download
Positions in Tuberculosis Research Available:
Selected Recent TB Articles/Publications
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance Cochrane Database Syst Review
Human genetics of mycobacterial disease. Mamm Genome
Tuberculosis in Pregnancy: A Treacherous Yet Neglected Issue J Obstet Gynaecol Can.